Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIASTAT ACUDIAL vs SYMPAZAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.
SYMPAZAN (clobazam) is a benzodiazepine that potentiates GABAergic inhibition via binding to the GABA-A receptor at the benzodiazepine site, enhancing chloride ion influx and neuronal hyperpolarization.
Status epilepticus,Acute repetitive seizures,Adjunctive treatment for epilepsy
FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older,Off-label: adjunctive therapy for other epileptic syndromes, anxiety disorders, and acute repetitive seizures
2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.
10-20 mg orally three times daily (maximum 60 mg/day). If switching from another benzodiazepine, use equivalent dose.
Terminal elimination half-life: 20-50 hours in adults; prolonged in elderly and patients with hepatic impairment (up to 100 hours).
Terminal elimination half-life is approximately 20-30 minutes sublingually, prolonged to 2-3 hours in hepatic impairment. Clinical context: Short t½ necessitates repeated dosing for seizure clusters.
Hepatic via CYP2C19, CYP3A4, and CYP2B6; major metabolite is N-desmethyldiazepam (active); also forms oxazepam and temazepam.
Primarily metabolized by CYP3A4 and CYP2C19 to N-desmethylclobazam, an active metabolite. N-desmethylclobazam is further metabolized by CYP2C19.
Primarily renal (urinary) as glucuronide conjugates and unchanged drug; <2% excreted unchanged in feces.
Primarily renal excretion of unchanged drug (approximately 60-70%), with minor fecal elimination (10-15%) and metabolism.
97-99% bound primarily to albumin.
Approximately 90-95% bound to albumin and alpha-1-acid glycoprotein.
0.8-1.4 L/kg (adults); reflects extensive distribution into tissues including brain.
Vd is 1-2 L/kg, indicating extensive tissue distribution beyond plasma volume.
Rectal gel: 80-100% relative to intravenous administration.
Sublingual and buccal: 100% bioequivalent to intravenous; intranasal: approximately 80%.
No specific dose adjustment provided in labeling; use with caution in severe renal impairment (Cr Cl < 10 m L/min) due to propylene glycol content.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution and consider dose reduction; specific guidelines not established.
Dose reduction may be necessary in Child-Pugh Class C cirrhosis; avoid in severe hepatic impairment due to decreased clearance and propylene glycol accumulation.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), reduce dose by 50% or administer with caution, as clobazam is extensively metabolized in the liver.
2 to 5 years: 0.5 mg/kg rectally; 6 to 11 years: 0.3 mg/kg; 12 years and older: 0.2 mg/kg. Dose per treatment episode not to exceed 20 mg.
Based on body weight: 5 mg orally once daily for <30 kg, increase to 10 mg daily after 2 weeks if needed (max 20 mg/day). For ≥30 kg, 5-10 mg once daily initially, titrate to 20 mg/day (max 40 mg/day).
Start at lower end of dosing range (2.5-5 mg) due to increased sensitivity and decreased clearance; monitor for excessive sedation and respiratory depression.
Initiate at 5 mg once daily, titrate slowly due to increased sensitivity to benzodiazepines and risk of falls. Maximum dose generally not to exceed 20 mg/day.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate response to alternatives.
Concomitant use of benzodiazepines with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Risk of respiratory depression, particularly with high doses or in elderly/chronically ill; tolerance and dependence; withdrawal symptoms; may impair cognitive and motor functions; should not be abruptly discontinued.
Respiratory depression,Sedation and somnolence,Risk of abuse, misuse, and addiction,Dependence and withdrawal reactions,Suicidal thoughts or behavior
Hypersensitivity to diazepam or benzodiazepines; narrow-angle glaucoma; severe respiratory insufficiency; myasthenia gravis; concomitant use with opioids (except for palliative care).
Hypersensitivity to clobazam or any component of the formulation,Severe hepatic impairment (Child-Pugh Class C)
Grapefruit and grapefruit juice may increase diazepam levels and risk of toxicity; avoid concurrent consumption. Alcohol potentiates CNS depression and should be avoided. No other significant food interactions reported.
Avoid grapefruit and grapefruit juice as they may increase levels of clobazam and its active metabolite. No other significant food interactions known.
DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters, chronic use may lead to fetal benzodiazepine exposure; high doses near term can cause neonatal withdrawal (hypertonia, irritability, tremors, poor feeding) and 'floppy infant syndrome' (hypotonia, lethargy, respiratory depression). No known structural teratogenicity in later trimesters.
Benzodiazepines are generally associated with increased risk of oral clefts when used in the first trimester. Use in the third trimester may cause neonatal sedation, withdrawal, or floppy infant syndrome. Specific fetal risk data for clobazam (Sympazan) are limited.
Diazepam is excreted into breast milk; M/P ratio is approximately 0.1-0.3. Relative infant dose estimated at 1-10% of maternal weight-adjusted dose. Neonatal accumulation possible due to long half-life (50-100 hours in preterm neonates). Breastfeeding is not recommended during chronic use due to risks of sedation, poor feeding, and withdrawal. Short-term, single-dose use may be acceptable with monitoring.
Clobazam is excreted in breast milk. The milk-to-plasma ratio is approximately 0.3 to 0.5. Monitor infant for sedation, poor feeding, and weight gain. Avoid breastfeeding if possible.
Pregnancy increases volume of distribution and decreases albumin concentration, potentially reducing diazepam peak levels. However, drug clearance is unchanged or slightly decreased. Dose adjustments are individually determined based on clinical response; no fixed rule. Lower initial doses may be considered in third trimester due to enhanced drug sensitivity. After delivery, reduce dose to pre-pregnancy levels.
Increased clearance of clobazam in pregnancy may require dose adjustments; monitor therapeutic response and adjust accordingly.
DIASTAT ACUDIAL is a diazepam rectal gel formulation used for acute repetitive seizures. Administer rectally; position patient on side to reduce aspiration risk. Do not administer more than 5 doses per month or more than 2 doses per single seizure episode. Monitor respiratory depression, especially with concurrent CNS depressants. Onset of action is 5-15 minutes; if seizure persists beyond 15 minutes, seek emergency medical attention. Avoid use in patients with acute narrow-angle glaucoma or severe liver disease.
Clobazam oral film (SYMPAZAN) is a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older. It is available as a rapidly dissolving film that can be placed on the tongue. The active metabolite N-desmethylclobazam is primarily renally excreted; adjust dose in renal impairment. Avoid abrupt discontinuation due to risk of withdrawal seizures. CYP2C19 poor metabolizers have significantly higher exposure to the active metabolite; consider dose reduction. Can cause sedation, dizziness, and somnolence; monitor for respiratory depression especially with other CNS depressants. Abuse potential exists; use with caution in patients with history of substance abuse.
Use exactly as prescribed; do not exceed recommended doses.,Insert the rectal gel tip gently and hold buttocks together for 1-2 minutes after administration.,Keep a seizure diary to track episodes and medication use.,Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while using this drug.,Seek medical help if seizures worsen or if breathing difficulties occur.,Store at room temperature away from light and moisture.
Place the film on your tongue where it will dissolve quickly; do not chew or swallow it whole.,Take this medication exactly as prescribed; do not increase the dose or stop suddenly without talking to your doctor to avoid withdrawal seizures.,Avoid driving or operating heavy machinery until you know how this drug affects you, as it may cause drowsiness, dizziness, or blurred vision.,Avoid alcohol and other sedating medications while taking SYMPAZAN, as they can increase the risk of severe drowsiness and breathing problems.,Tell your doctor if you have kidney or liver disease, or if you have a history of substance abuse or depression.,If you miss a dose, take it as soon as you remember; if it is close to the next dose, skip the missed dose and continue your regular schedule. Do not double the dose.,Store the film at room temperature away from moisture and heat; keep each film in its sealed pouch until ready to use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIASTAT ACUDIAL vs SYMPAZAN, answered by our medical review team.
DIASTAT ACUDIAL is a Benzodiazepine Anticonvulsant that works by Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.. SYMPAZAN is a Benzodiazepine Anticonvulsant that works by SYMPAZAN (clobazam) is a benzodiazepine that potentiates GABAergic inhibition via binding to the GABA-A receptor at the benzodiazepine site, enhancing chloride ion influx and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIASTAT ACUDIAL and SYMPAZAN depend on the specific clinical indication. These are both Benzodiazepine Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIASTAT ACUDIAL is: 2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.. The standard adult dose of SYMPAZAN is: 10-20 mg orally three times daily (maximum 60 mg/day). If switching from another benzodiazepine, use equivalent dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIASTAT ACUDIAL and SYMPAZAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIASTAT ACUDIAL is classified as Category C. DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters. SYMPAZAN is classified as Category C. Benzodiazepines are generally associated with increased risk of oral clefts when used in the first trimester. Use in the third trimester may cause neonatal sedation, withdrawal, or. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.